We advised Oxipit, a Lithuanian startup specialising in AI-based solutions for radiology, on the sale of its shares to Sectra, an international medical imaging IT and cybersecurity company. Oxipit holds the first CE Class IIB certification for autonomous AI in chest X-ray analysis.
Oxipit’s ChestLink is a leading example of this autonomous approach. Within its defined clinical scope, it is designed to automatically identify and clear high-confidence normal chest X-ray examinations from the radiologist’s worklist. This allows radiologists to focus their expertise on cases with a higher probability of disease.
The Oxipit team will operate as a dedicated AI development center within Sectra’s Imaging IT Solutions operating area. Alongside Sectra’s own capabilities, Sectra’s Amplifier service will remain an open, vendor-neutral ecosystem, providing healthcare providers access to AI applications from a wide range of vetted partners.
Oxipit was founded in 2017 and has developed a portfolio of CE-marked AI solutions for radiology spanning chest X-ray, CT, and musculoskeletal imaging. The solutions are currently deployed across multiple markets internationally.
Our team and services
Our team, including partner Mantas Petkevičius, senior associate Mindaugas Baniulis, associates Povilas Užkuraitis, Goda Jakubauskaitė and Barbora Bernatonytė, and assistant lawyer Povilas Virbašius, advised Oxipit on all transaction-related matters, including preparation for the sale, negotiations with buyers, and transaction documentation drafting.
This marks a successful exit for a Lithuanian startup. The Sorainen team advised Oxipit from its founding and throughout all investment rounds since then.
